Shots:

• The companies collaborated to evaluate the use of immunoSEQ T-MAP- for which Adaptive will receive quarterly payments + sequencing and data mapping fees
• AstraZeneca to provide cancer patients’ biological samples while Adaptive will sequence the samples & deliver TCR-antigen mapping data using its clinical immunomics database of 58B+ immune cell receptors and antigens
• AstraZeneca gets an option to enter into an agreement with Adaptive for the development & commercialization of a CDx or therapeutic application based on T-MAP data. ImmunoSEQ T-MAP combines the sequencing and mapping capabilities of Adaptive to map TCRs to antigens- across AZ’s oncology portfolio

 ­ Ref: Adaptive | Image: Business Standard